Interferon Patents (Class 424/85.4)
-
Publication number: 20150086477Abstract: Provided herein are methods and computer-readable storage media related to cell-free DNA and uses thereof to determine risk of a condition, such as transplant rejection or cancer, in a subject.Type: ApplicationFiled: April 19, 2013Publication date: March 26, 2015Applicant: Medical College of Wisconsin, Inc.Inventors: Aoy Tomita Mitchell, Michael Mitchell
-
Patent number: 8986670Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.Type: GrantFiled: February 28, 2013Date of Patent: March 24, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
-
Publication number: 20150079033Abstract: The non-invasive methods described herein generally relates to methods of detecting bladder cancer or bladder cancer recurrence. The methods involve identifying a cutoff level for a protein biomarker parameter to provide a predetermined sensitivity for an assay, in which the measured biomarker parameter values below a defined cutoff level is indicative of the absence of cancer and measured biomarker parameter values above a defined cutoff level are indicative of the presence of cancer. The method can also involve establishing a cutoff level for two or more nucleic acid markers in which the nucleic acid markers increase the specificity of the assay without decreasing the sensitivity of the assay, and in which the cutoff level is indicative of the absence of cancer.Type: ApplicationFiled: November 14, 2014Publication date: March 19, 2015Inventors: Anthony P. Shuber, Cecilia Fernandez
-
Patent number: 8980245Abstract: The present application discloses new PEG-interferon lambda 1 conjugates (PEG-IFN?1), processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same. These conjugates have increased blood half-lives and persistence time compared to IFN?1 and are effective in the treatment of hepatitis B and hepatitis C.Type: GrantFiled: May 1, 2013Date of Patent: March 17, 2015Assignee: Nanogen Pharmaceutical BiotechnologyInventor: Nhan Ho
-
Publication number: 20150071878Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 12, 2014Publication date: March 12, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
-
Publication number: 20150071879Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).Type: ApplicationFiled: October 17, 2014Publication date: March 12, 2015Inventor: Jan JEZEK
-
Patent number: 8968717Abstract: The invention provides a multi-compartmented container suitable for the delivery of pharmaceuticals, medicines, vitamins, and the like.Type: GrantFiled: October 14, 2008Date of Patent: March 3, 2015Assignee: Capsugel Belgium NVInventors: Clinton Wesley McInnes, Anna Marie Underwood, Phillip Andrew Vickery
-
Publication number: 20150056164Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.Type: ApplicationFiled: April 24, 2014Publication date: February 26, 2015Applicant: AbbVie Inc.Inventors: David A. Betebenner, John K. Pratt, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Kenton L. Longenecker, Clarence J. Maring, John T. Randolph, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Dachun Liu
-
Publication number: 20150056165Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.Type: ApplicationFiled: August 26, 2014Publication date: February 26, 2015Inventors: Yat Sun Or, Guoqiang Wang, Jiang Long, In Jong Kim
-
Patent number: 8962811Abstract: Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed.Type: GrantFiled: April 3, 2013Date of Patent: February 24, 2015Assignee: Ohio UniversityInventors: Marcia J. Kieliszewski, Jianfeng Xu, John Kopchick, Shigeru Okada, Gary Meyer
-
Publication number: 20150050241Abstract: The present invention is directed to methods and compositions employing 9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine (“H2G”) or derivatives or analogs thereof for the treatment of viral diseases, as well as for the treatment of other conditions, including, but not limited to, cancer, chronic fatigue syndrome, Alzheimer's disease, multiple sclerosis and Graves' disease. The H2G or derivative or analog thereof can be administered in a pharmaceutical composition and can be administered with an additional antiviral therapeutic agent or another agent for the treatment of other conditions.Type: ApplicationFiled: October 30, 2014Publication date: February 19, 2015Inventors: Fred VOLINSKY, Steven Daniel DONG
-
Publication number: 20150050239Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: July 19, 2013Publication date: February 19, 2015Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
-
Publication number: 20150050240Abstract: This invention is in the field of treatment of fibrosis. In particular, it relates to the treatment of IPF using N-Cadherin antibodies. The antibody may be any antagonising or neutralizing N-Cadherin antibody suitable for therapeutic use.Type: ApplicationFiled: March 13, 2013Publication date: February 19, 2015Applicant: NOVARTIS AGInventors: Irena Rumenova Konstantinova, Andrew Christopher Pearce
-
Publication number: 20150050356Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.Type: ApplicationFiled: October 28, 2014Publication date: February 19, 2015Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Vuong TRIEU
-
Publication number: 20150044167Abstract: The present invention provides means and methods for determining whether a hepatitis B patient is susceptible to hepatitis B treatment, comprising determining whether a sample of the patient comprises nucleic acid with nucleotide polymorphisms that are associated with a positive outcome of hepatitis B treatment and/or determining whether a sample of the patient comprises an expression level of carnitine or of a carnitine derivative that is associated with a positive outcome of hepatitis B treatment. Compositions, kits of parts, (micro)arrays and vectors useful for such methods are also herewith provided.Type: ApplicationFiled: March 19, 2013Publication date: February 12, 2015Applicant: Academisch Medisch CentrumInventors: Hendrik Willem Reesink, Louis Jansen, Neeltje Akke Kootstra
-
Publication number: 20150037280Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: July 19, 2013Publication date: February 5, 2015Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
-
Publication number: 20150030563Abstract: The present invention relates to the treatment, alleviation, prevention or reduction in the incidence of symptoms, diseases or conditions resulting from or associated with enteroviruses, more particularly the enteroviral infections they cause.Type: ApplicationFiled: August 5, 2014Publication date: January 29, 2015Inventors: Johan NEYTS, Armando De Palma, Hendrik Jan Thibaut, Pieter Leyssen, Simon Tucker
-
Publication number: 20150030564Abstract: An inhibitory agent for body cavity fluid accumulation exerts a drug efficacy on body cavity fluid accumulation that is resistant to administration of diuretics, and is capable of exerting therapeutic effects even by systemic administration. The inhibitory agent for body cavity fluid accumulation includes, as an active ingredient, a covalent conjugate of interferon with polyalkylene glycol.Type: ApplicationFiled: February 28, 2013Publication date: January 29, 2015Applicant: Toray Industries, Inc.Inventors: Hideki Narumi, Sanae Ikehara
-
Publication number: 20150023913Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.Type: ApplicationFiled: July 2, 2013Publication date: January 22, 2015Inventors: Piyasena Hewawasam, Omar D. Lopez, Yong Tu, Alan Xiangdong Wang, Ningning Xu, John F. Kadow, Nicholas A. Meanwell, Samayamuthula Venkata Satya Arun Kumar Gupta, Indasi J. Gopi Kumar, Suresh Kumar Ponugupati, Makonen Belema
-
Publication number: 20150023914Abstract: Methods for treating skin conditions such as basal cell carcinoma and/or actinic keratosis are provided, which are effected by administering a pharmaceutically effective amount of a tellurium-containing compound. A pharmaceutical composition for treatment of skin conditions such as basal cell carcinoma and/or actinic keratosis is also provided.Type: ApplicationFiled: April 21, 2014Publication date: January 22, 2015Applicant: BioMAS Ltd.Inventors: Benjamin SREDNI, Michael ALBECK
-
Publication number: 20150023916Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family such as Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever.Type: ApplicationFiled: February 14, 2013Publication date: January 22, 2015Applicant: SIGA TECHNOLOGIES INC.Inventors: Dongcheng Dai, James R. Burgeson, Sean M. Amberg, Dennis E. Hruby
-
Publication number: 20150023917Abstract: The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis B and Hepatitis D virus infections.Type: ApplicationFiled: July 28, 2014Publication date: January 22, 2015Applicant: NOVARTIS AGInventor: Nikolai Naoumov
-
Publication number: 20150023915Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides.Type: ApplicationFiled: May 16, 2014Publication date: January 22, 2015Applicant: The Board of Regents of the University of Texas SystemInventors: Sean MORRISON, Ugur ESKIOCAK
-
Patent number: 8936781Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: April 13, 2010Date of Patent: January 20, 2015Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yonghua Gai, Yat Sun Or, Guoqiang Wang
-
Publication number: 20150010507Abstract: The present disclosure is directed to compositions and methods for treating or preventing muscle injury or diseases through oral administration of low doses of type I and/or type III interferons. In one embodiment a composition is administered comprising interferon-alpha and trehalose.Type: ApplicationFiled: July 3, 2014Publication date: January 8, 2015Inventor: Joseph Cummins
-
Publication number: 20150010504Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.Type: ApplicationFiled: February 9, 2013Publication date: January 8, 2015Applicant: Lupin LimitedInventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20150010502Abstract: Compositions and methods for inhibition of p53 and clusterin expression in target cells for the treatment of disease are disclosed.Type: ApplicationFiled: July 12, 2012Publication date: January 8, 2015Inventor: Larry J. Smith
-
Publication number: 20150010495Abstract: The present invention relates to a method for producing or identifying a MUC1 molecule which is able to generate an immune response in humans. The invention also relates to a method for producing or identifying a cell, cell lines or cell lysates containing a MUC1 molecule that is able to generate an immune response in humans. The invention further relates to methods for producing medicaments and diagnostic agents. Also disclosed is the use of the MUC1 molecules, cells or cell lysates obtained by means of the methods according to the invention for producing a medicament used for treating or preventing tumours. Further disclosed is a purified MUC1 molecule that can be obtained by means of the methods according to the invention and has an immunostimulating effect on humans. The invention additionally relates to the use of a MUC1 antibody for the production of a medicament used for treating or preventing tumours.Type: ApplicationFiled: January 6, 2014Publication date: January 8, 2015Applicant: GLYCOTOPE GMBHInventors: Steffen Goletz, Uwe Karsten
-
Publication number: 20150010503Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.Type: ApplicationFiled: February 21, 2013Publication date: January 8, 2015Applicant: The University of ChicagoInventors: Russell Z. Szmulewitz, Suzanne D. Conzen
-
Patent number: 8927484Abstract: The present application includes novel inhibitors of HCV, compositions containing such compounds, therapeutic methods that include the administration of such compounds.Type: GrantFiled: December 1, 2010Date of Patent: January 6, 2015Assignee: Gilead Sciences, Inc.Inventors: Zhenhong R. Cai, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Mingzhe Ji, Choung U. Kim, Hyung-jung Pyun, Xiaoning C. Sheng, Qiaoyin Wu
-
Publication number: 20150004134Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.Type: ApplicationFiled: December 3, 2013Publication date: January 1, 2015Applicant: CALITHERA BIOSCIENCES, INC.Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
-
Publication number: 20150004135Abstract: The present disclosure relates to compounds of Formula (I): Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of using the compounds of Formula (I) and/or compositions comprising the compounds of Formula (I) for the treatment of HCV.Type: ApplicationFiled: December 17, 2012Publication date: January 1, 2015Applicants: HOFFMAN-LA ROCHE INC., RIBOSCIENCE LLCInventors: Jing Zhang, Zhuming Zhang
-
Publication number: 20140377173Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.Type: ApplicationFiled: June 24, 2014Publication date: December 25, 2014Inventors: David V. Gold, David M. Goldenberg
-
Patent number: 8916616Abstract: Multifunctional polymers are disclosed having a smart segment and a biodegradable segment. Advantageously, the biodegradable segment includes a hydrophilic segment and a hydrophobic segment. Embodiments include combining the multifunctional polymeric material with a biologically active substance in an aqueous loading environment and administering the composition as a drug delivery vehicle to a human subject.Type: GrantFiled: August 27, 2013Date of Patent: December 23, 2014Assignee: University of Tennessee Research FoundationInventors: Tao Lu Lowe, Young Shin Kim, Xiao Huang
-
Publication number: 20140369961Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.Type: ApplicationFiled: August 28, 2014Publication date: December 18, 2014Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
-
Publication number: 20140369960Abstract: Novel biologically active compounds of the general formula (I) in which one of X and X? represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X? represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X? and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z1 and Z2 independently represents a group derived from a biological molecule, each of which is linked to A and B via an amine group; or Z1 and Z2 together represent a single group derived from a biological molecule which is linked to A and B via two amine groups; A is a C1-5 alkylene or alkenylene chain; and B is a bond or a C1-4 alkylene or alkenylene chain; are formed by conjugating a suitable polymer to a suitable biologically active molecule via amine groups in saiType: ApplicationFiled: July 28, 2014Publication date: December 18, 2014Inventors: Stephen James BROCCHINI, Antony Robert Godwin, Elisa Pedone, Ji-Won Choi, Sunil Shaunak
-
Publication number: 20140369959Abstract: The present invention relates to the use of nucleoside derivatives of formula (I) wherein the symbols are as the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: December 17, 2012Publication date: December 18, 2014Inventors: Mark Smith, Francisco Xavier Talamas, Jing Zhang, Zhuming Zhang
-
Publication number: 20140363395Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.Type: ApplicationFiled: July 24, 2014Publication date: December 11, 2014Inventors: Theodore J. Nitz, Janet A. Gaboury, Christopher J. Burns, Sylvie Laquerre, Daniel C. Pevear, Thomas A. Lessen, David J. Rys
-
Publication number: 20140363396Abstract: Hepatitis C is treated by administering once daily ribavirin, taribavirin, other derivatives or pharmaceutically acceptable salts thereof. Hepatitis C may also be treated by administering any of the foregoing compounds once daily in combination with interferon and/or direct-acting antivirals. Once daily dosage forms administered for treating hepatitis C may comprise between 800 mg and 1400 of ribavirin. Once daily dosage forms administered for treating hepatitis C may also comprise between 800 mg and 4000 mg of taribavirin.Type: ApplicationFiled: February 1, 2013Publication date: December 11, 2014Applicant: KADMON PHARMACEUTICALS LLCInventor: Samuel Waksal
-
Publication number: 20140356321Abstract: Granulin-epithelin precursor (GEP), a pluripotent growth factor, is a hepatic oncofetal protein defining a cancer stem cell (CSC) population in liver cancer. The present invention provides the use of GEP inhibitors (including anti-GEP antibody) for inhibiting immune evasion by liver cancer cells and for eliminating liver cancer stem cells.Type: ApplicationFiled: May 30, 2014Publication date: December 4, 2014Applicant: THE UNIVERSITY OF HONG KONGInventors: Siu Tim Cheung, Sheung-Tat Fan, Phyllis Fung Yi Cheung
-
Publication number: 20140356324Abstract: This invention provides crystalline recombinant interferon (rSIFN-co (SEQ ID NO: 1)) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-?2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structural model of said interferon useful for drug screening and/or drug design, and mimetics of said interferon.Type: ApplicationFiled: August 15, 2014Publication date: December 4, 2014Inventors: Guangwen WEI, Dacheng Wang
-
Patent number: 8901157Abstract: The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof.Type: GrantFiled: December 2, 2010Date of Patent: December 2, 2014Assignee: AbbVie Inc.Inventors: Dale J. Kempf, Kennan C. Marsh
-
Patent number: 8900566Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: September 18, 2013Date of Patent: December 2, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Makonen Belema, Van N. Nguyen
-
Publication number: 20140348936Abstract: Gastroretentive controlled release vehicles may, in some embodiments, (1) comprise a polymeric matrix and agents for the treatment, prevention, and/or mitigation of a disease and/or side effect thereof and (2) have both gastroretentive properties and controlled release properties. Preferrably, the polymeric matrix may comprise ethylene copolymers, ethyl celluloses, and/or thermoplastic polyurethanes that may optionally be partially crosslinked.Type: ApplicationFiled: December 17, 2012Publication date: November 27, 2014Inventors: Jose Reyes, Kenneth Anderson, Dale Zevotek, Nathan Reuter, J. Gregory Little, Jeffrey Haley, Vassilios Galiatsatos
-
Publication number: 20140348787Abstract: Compositions and methods for treating ear infections are disclosed. More specifically, these methods may refer to treatment of internal otitis using an otic composition, such as otic gel for animals and humans. Poloxamer otic gel may be in liquid state at room temperature and may change to gel at about temperature (64° F.) as poloxamer otic gel reaches body temperature, because of the thermo-reversible properties. Consequently, poloxamer otic gel may be an effective treatment in animals and humans, where poloxamer otic gel may reach otitis affected site and remain there for a longer period of time. Additionally, poloxamer otic gel may include APIs such as antifungals, antibiotics and corticosteroids, among others. Furthermore, poloxamer otic gel may be instilled inside the ear, employing calibrated delivery device into the vertical ear canal in order to reach the horizontal ear canal, without puncturing the tympanic membrane.Type: ApplicationFiled: May 22, 2013Publication date: November 27, 2014Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICAInventor: Chris V. Simmons
-
Patent number: 8895700Abstract: Cytokine IFN? nucleic acids from the Cynomolgus monkey are useful for expression of IFN? proteins that are functional homologs of human IFN?. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of IFN?, the generation and testing of IFN? modulators and related activities.Type: GrantFiled: February 16, 2011Date of Patent: November 25, 2014Assignee: Janssen Biotech, Inc.Inventors: Chichi Huang, Jarrat Jordan, Jessica Schreiter
-
Publication number: 20140341850Abstract: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.Type: ApplicationFiled: August 5, 2014Publication date: November 20, 2014Applicant: Romark Laboratories, L.C.Inventors: Jean-Francois Rossignol, J. Edward Semple
-
Publication number: 20140341851Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 4, 2014Publication date: November 20, 2014Applicant: ENANTA PHARMACEUTICALS, INC.Inventors: YAO-LING QIU, Ce Wang, Xiaowen Peng, Hui Cao, Lu Ying, Xuri Gao, Bin Wang, Yat Sun Or
-
Publication number: 20140341847Abstract: The present disclosure relates to the compound of Formula I: Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.Type: ApplicationFiled: May 15, 2014Publication date: November 20, 2014Applicant: Riboscience LLCInventors: Mark Smith, Klaus G. Klumpp
-
Publication number: 20140341849Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Deng PAN, Masha Kocherginsky, Suzanne D. Conzen